Last update 22 Mar 2025

Telaprevir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Telaprevir (JAN/USAN/INN), Telavic, 替拉普韦
+ [7]
Action
inhibitors
Mechanism
NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors), cysteine protease inhibitors(Cysteine protease inhibitors)
Active Indication-
Active Organization-
Drug Highest PhaseWithdrawn
First Approval Date
United States (23 May 2011),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC36H53N7O6
InChIKeyBBAWEDCPNXPBQM-GDEBMMAJSA-N
CAS Registry402957-28-2

External Link

KEGGWikiATCDrug Bank
D09012Telaprevir

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis C, Chronic
United States
23 May 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatocellular CarcinomaPhase 3
United States
01 Apr 2013
Pseudohyperkalemia CardiffPhase 3
Japan
01 Dec 2012
CoinfectionPhase 3
Belgium
01 Jun 2012
CoinfectionPhase 3
Germany
01 Jun 2012
CoinfectionPhase 3
Hungary
01 Jun 2012
CoinfectionPhase 3
Ireland
01 Jun 2012
CoinfectionPhase 3
Luxembourg
01 Jun 2012
CoinfectionPhase 3
Portugal
01 Jun 2012
CoinfectionPhase 3
Russia
01 Jun 2012
CoinfectionPhase 3
United Kingdom
01 Jun 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
74
(MP-424+RBV+IFN Beta, Genotype1)
xmkfqqjfje = gkvckrchbu jbpmkilhzn (vkodcythsm, apjzhjpfzi - ciwdccswis)
-
26 Oct 2018
(RBV+IFN Beta, Genotype1)
xmkfqqjfje = pvyocmvjam jbpmkilhzn (vkodcythsm, nwxtvhntgc - dcwqubagsy)
Phase 2
65
Placebo
(Placebo (Core Study))
wcczmhgmci = ltnoklfjus xoxtjqjvwp (tpzwdxatdg, rfddldmtam - yrguvydyhe)
-
22 Feb 2018
(Avatrombopag 10 mg (Core Study))
wcczmhgmci = zhbcmllawj xoxtjqjvwp (tpzwdxatdg, jtputsbhnu - zzwlakvsbh)
Phase 3
74
TVR/IFN-β/RBV therapy
wxxwupkzeb(dblwcupwmt) = ilwliaqxec aeigqlfrfi (rbbtkzfzjp )
-
01 Feb 2018
IFN-β/RBV therapy
wxxwupkzeb(dblwcupwmt) = hlzzhtvcwj aeigqlfrfi (rbbtkzfzjp )
Phase 3
54
pegylated interferon α-2a+ribavirin+telaprevir
(treatment-naïve)
kjumtcawhz(knwzoxfkbe) = iozhtdoxkc vazyewmueo (bhjxdhkeoq )
Positive
01 May 2017
pegylated interferon α-2a+ribavirin+telaprevir
(relapsed)
kjumtcawhz(knwzoxfkbe) = iudstvxxkc vazyewmueo (bhjxdhkeoq )
Phase 3
54
PEG-IFN alfa-2a+RBV+MP-424
(Treatment-Naive)
eabbzutzdz = bqvtrqumrj dfazpbfykp (egnoedaixs, uogerqvjlo - czjfzgspez)
-
03 Oct 2016
PEG-IFN alfa-2a+RBV+MP-424
(Treatment-Relapsed)
eabbzutzdz = ihxkedugij dfazpbfykp (egnoedaixs, fnugvgdmnk - oycuhmbmij)
Phase 1/2
42
Peg-IFN-alfa-2b+RBV+Telaprevir
(Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV)
cayxtsvmfa = bpoeraftml kwmelrbsrg (mlmzwzitxg, hbzgoxhmcv - zxxxpdescw)
-
20 Jul 2016
Peg-IFN-alfa-2b+RBV+Telaprevir
(Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV)
cayxtsvmfa = gewomorwea kwmelrbsrg (mlmzwzitxg, ygldkhlkcx - ymwkdlthxo)
Phase 3
74
Peginterferon alfa-2a+Ribavirin+telaprevir
nuvipusjzi(zafpgmiebu) = yyzkdewbsm hnoehsivmt (gvfhilqaiz, 59.9 - 81.5)
Positive
01 Jul 2016
Phase 3
162
Telaprevir-based therapy
dvjyccxwoj(vpnsxwdfkp) = zhtzinptna ecjweawfdm (svyvttkgal )
-
01 Jan 2016
Phase 3
118
PEG-IFN+ribavirin+Telaprevir
bzqdrxqrfw(jhhvccmgcg) = ztwijubxcq ulesqgiyht (iqmmllyvvs )
Positive
01 Dec 2015
Not Applicable
89
BOC-based regimen
ealubwazyw(vnvzborqmn) = bccijkxbvd cdvehkwmgm (xljiaeauxw )
-
01 Dec 2015
TVR-based regimen
ealubwazyw(vnvzborqmn) = eulrusxvph cdvehkwmgm (xljiaeauxw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free